A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular disease by 22%. The SELECT trial results highlight semaglutide's benefits for kidney function and overall cardiovascular health.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
